Orally or rectally in adults and adolescents weighing more than 60 kg is used in a single dose of 500 mg, the frequency of administration is up to 4 times / day. The maximum duration of treatment is 5-7 days.

Maximum doses: single - 1 g, daily - 4 g.

Single doses for oral administration for children aged 6-12 years - 250-500 mg, 1-5 years - 120-250 mg, from 3 months to 1 year - 60-120 mg, up to 3 months - 10 mg / kg. Single doses for rectal administration in children aged 6-12 years - 250-500 mg, 1-5 years - 125-250 mg.

Frequency rate of application - 4 times / day with an interval of at least 4 hours. The maximum duration of treatment is 3 days.

Maximum dose: 4 single doses per day

Application during pregnancy and lactation

Paracetamol crosses the placental barrier. To date, no negative effects of paracetamol on the fetus in humans have been noted.

Paracetamol is excreted in breast milk: the content in milk is 0.04-0.23% of the dose taken by the mother.

If it is necessary to use paracetamol during pregnancy and lactation (breastfeeding), the expected benefits of therapy for the mother and the potential risk for the fetus or child should be carefully weighed.

In experimental studies, the embryotoxic, teratogenic and mutagenic effects of paracetamol have not been established.

Chronic alcoholism, hypersensitivity to paracetamol.

On the part of the digestive system: rarely - dyspeptic phenomena, with prolonged use in high doses - hepatotoxic effect.

From the hematopoietic system: rarely - thrombocytopenia, leukopenia, pancytopenia, neutropenia, agranulocytosis.

Allergic reactions: rarely - skin rash, itching, urticaria.

With the simultaneous use with inducers of microsomal liver enzymes, agents with hepatotoxic action, there is a risk of increased hepatotoxic action of paracetamol.

With simultaneous use with anticoagulants, a slight or moderate increase in prothrombin time is possible.

With simultaneous use with anticholinergics, it is possible to reduce the absorption of paracetamol.

With simultaneous use with oral contraceptives, the elimination of paracetamol from the body is accelerated and its analgesic effect may decrease.

When used simultaneously with uricosuric agents, their effectiveness decreases.

With the simultaneous use of activated carbon, the bioavailability of paracetamol decreases.

With simultaneous use with diazepam, it is possible to reduce the excretion of diazepam.

There are reports of the possibility of enhancing the myelodepressant effect of zidovudine when used simultaneously with paracetamol. A case of severe toxic liver damage is described.

Cases of manifestations of the toxic effect of paracetamol with simultaneous use with isoniazid are described.

When used simultaneously with carbamazepine, phenytoin, phenobarbital, primidone, the effectiveness of paracetamol decreases, which is due to an increase in its metabolism (glucuronization and oxidation processes) and excretion from the body. Cases of hepatotoxicity with the simultaneous use of paracetamol and phenobarbital have been described.

When using cholestyramine for a period of less than 1 hour after taking paracetamol, the absorption of the latter may decrease.

With simultaneous use with lamotrigine, the excretion of lamotrigine from the body is moderately increased.

With simultaneous use with metoclopramide, an increase in the absorption of paracetamol and an increase in its concentration in blood plasma is possible.

With simultaneous use with probenecid, it is possible to reduce the clearance of paracetamol; with rifampicin, sulfinpyrazone - an increase in paracetamol clearance is possible due to an increase in its metabolism in the liver.

With simultaneous use with ethinyl estradiol, the absorption of paracetamol from the intestine increases.

Use with caution in patients with impaired liver and kidney function, with benign hyperbilirubinemia, as well as in elderly patients.

With prolonged use of paracetamol, it is necessary to control the picture of peripheral blood and the functional state of the liver.